Surf Air Mobility

TALARIS THERAPEUTICS (NASDAQ: TALS) STOCK QUOTE

Last Trade: US$2.72
Volume: 0
5-Day Change: 0%
YTD Change: 0%
Market Cap: US$116.440M

LATEST NEWS FROM TALARIS THERAPEUTICS

Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the proposal to approve the... Read More
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline... Read More
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with... Read More
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) Combined company expected to have approximately $210 million of cash at the transaction close, including approximately $75 million from a concurrent private placement with leading life sciences investors Strong... Read More
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris’s Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as... Read More
BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily... Read More
BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore... Read More
Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients Two presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting. The first presentation... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients. On October 18, 2022, the Company received a report of a patient death, which... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced upcoming data presentations at the American Society of Nephrology (ASN) Annual Meeting, taking place November 3-6, 2022 in Orlando, Fla. Talaris will present data on the makeup of... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair’s Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday,... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Fireside chat date: Monday,... Read More
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase... Read More
GreenStockNews
All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker... Read More
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic complications than patients on immunosuppression after 5 years In long-term follow up of Phase 2 patients, all patients originally weaned off IS have continued to remain off IS without rejecting their donated kidney Update on FREEDOM-1 study originally planned... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022. A... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors. “Karen’s long track record of developing and commercializing novel... Read More
Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients Presented data on COVID-19 outcomes among kidney transplant patients treated with FCR001 Strong $225.5 million cash balance to fund operations Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy... Read More
D ata to be presented include real-world evidence analysis of health outcomes among Phase 2 patients compared to matched controls Updated data on Phase 2 study follow-up, COVID-19 patient outcomes also planned for ATC Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune... Read More
Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with COVID-19 infection No patients lost chimerism as a result of COVID-19 vaccination or infection Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences: Morgan Stanley Healthcare Corporate Access Day Date: Tuesday, March 29, 2022 Location: Boston... Read More
Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients continues; additional data update expected mid-year 2022 Two Phase 2 (FREEDOM-2 and FREEDOM-3) clinical trials of FCR001 initiated in delayed tolerance and scleroderma Robust $244 million cash balance to fund operations through multiple milestones Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET. A... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. A webcast of the... Read More
Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), active prior to market open... Read More
Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA mismatching between donors and recipients participating in the Company’s Phase 2 trial in living donor kidney transplant (LDKT). High-resolution allele typing at six loci found that FCR001 induced durable immune tolerance in highly mismatched related and unrelated recipients. The findings were shared... Read More
Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the initiation of the company’s Phase 2 FREEDOM-3 trial in diffuse cutaneous systemic sclerosis (dcSSc), a... Read More
Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation,... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences: Virtual... Read More
First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with stable kidney function All Phase 3 patients who received FCR001 at least three months prior to the data cutoff date achieved and maintained >50% T-cell chimerism, which in Phase 2 correlated strongly with long-term,... Read More
Talaris Therapeutics, Inc. , (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the initiation of the company’s Phase 2 FREEDOM-2 study. Northwestern University is the first FREEDOM-2... Read More
Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients Poster with additional data from Phase 2 study follow-up to be presented at ASN Talaris to host investor conference call on November 4, 2021, to discuss data Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences: Morgan... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three- and six-month periods ended June 30, 2021, and provided an update on its... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021, and provided an update on its business.... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced upcoming presentations of data from the company’s Phase 2 study of FCR001 at the American Transplant Congress taking... Read More
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS